Study identifier:D5160R00016
ClinicalTrials.gov identifier:NCT03133234
EudraCT identifier:N/A
CTIS identifier:N/A
An Observational, Retrospective, Real World Study of osimertinib in Ethnic Chinese Patients with Locally advanced/Metastatic T790M Mutation-Positive non-small-cell lung cancer (NSCLC )progressed on previous epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI).
T790M positive NSCLC patients
N/A
No
osimertinib
All
47
Observational
18 Years +
Allocation: N/A
Endpoint Classification: -
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: -
Verified 01 Nov 2018 by AstraZeneca
AstraZeneca
-
No locations available
Arms | Assigned Interventions |
---|---|
EGFR T790M Patients Patients with locally advanced/metastatic EGFR T790M positive NSCLC progressed on previous EGFR TKI | Drug: osimertinib Oral dose of 80mg once daily Other Name: NA |